期刊文献+

美罗培南治疗新生儿败血症疗效观察 被引量:3

下载PDF
导出
摘要 目的 探讨美罗培南在NICU治疗新生儿败血症的疗效。方法 对采用常规治疗无效的新生儿败血症患儿 1 5例应用美洛培南静脉治疗 ,1 5~ 2 0mg·kg-1 ·d-1 ,分 3次静脉滴注。临床疗效评价分为痊愈、显效、进步和无效。痊愈和显效作为有效统计。安全评价按照不良事件与药物因果关系分为有关、很可能有关、可能有关、可能无关和无关。结果 在治疗结束时 ,美罗培南疗效评价为痊愈 1 2例 ,显效 1例 ,进步 1例 ,无效 1例。总有效率为 86 .7%。无不良反应发生。结论 美罗培南特别适合用于NICU的严重新生儿败血症。疗效突出 ,无明显副作用 。
出处 《重庆医学》 CAS CSCD 2004年第4期523-524,共2页 Chongqing medicine
  • 相关文献

参考文献3

二级参考文献13

  • 1Klugman K P,Antimicrob Agents Chemother,1995年,39卷,1140页 被引量:1
  • 2Neu H C,Antimicrob Agents Chemother,1989年,33卷,1009页 被引量:1
  • 3Waterer GW, Wunderink RG. Increasing threat of gram-negative bacteria[J]. Crit Care Med, 2001, 29, 4(Suppl): N75-81 被引量:1
  • 4Mathai D, Lewis M T, Kugler KC, et al. Antibacterial activity of 41 antimicrobi als tested against over 2733 bacterial isolates from hospitalized patients with p neumonia: Results from the SENTRY antimicrobial surveillance program[J]. Di agn Microbiol Infect Dis, 2001, 39(2): 105-116 被引量:1
  • 5Fridkin SK. Increasing prevalence of antimicrobial resistance in intensive ca re units[J]. Crit Care Med, 2001, 29, 4(Suppl): N64-68 被引量:1
  • 6Hurst M, Lamb HM. Meropenem: a review of its use in patients in intensive care[J]. Drugs, 2000, 59(3): 653-680 被引量:1
  • 7Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5000 patients treated with meropenem[J]. Scand J Infect Dis, 1999, 31(1): 3-10 被引量:1
  • 8Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures i n seriously ill infected patients receiving antibiotics: experience with imipene m/cilastatin[J]. Am J Med, 1988, 84(5): 911-918 被引量:1
  • 9Wong VK, Wright HT Jr, Ross LA, et al. Imipenem/cilastatin treatment of bacte rial meningitis in children[J]. Pediatr Infect Dis J, 1991, 10(2): 122-125 被引量:1
  • 10Norrby SR. Neurotoxicity of carbapenem antibiotics: consequences for their us e in bacterial meningitis[J]. J Antimicrob Chemother, 2000, 45(1): 5-7 被引量:1

共引文献94

同被引文献24

  • 1李顺品,金德华,温沙洛.108例新生儿败血症的临床治疗分析[J].中国妇幼保健,2005,20(17):2208-2210. 被引量:1
  • 2王亚男.头孢曲松钠配伍舒巴坦钠治疗新生儿败血症的疗效观察[J].华北煤炭医学院学报,2006,8(5):684-684. 被引量:2
  • 3T M FILE,J SEGRETI, L DUNBAR,et al. A multicenter, randomized study comparing the efficacy and safety of intra- venous and/or oral levofloxaein versus eeftriaxone and/or ee- furoxime axetil in treatment of adults with community-ac- quired pneumonia[J]. Antimicrob Agents Chemother, 1997, 41 (9) : 1965-1972. 被引量:1
  • 4Clark R,Powers R,White R,et al.Nosocomial infection in the NICU:A medical complication or unavoidable problem[J]? J Perinatol,2004,24(6):382-388. 被引量:1
  • 5Krueger WA,Bulitta J,Kinzig-Schippers M,et al.Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers[J].Antimicrob Agents Chemother,2005,49 (5):1881-1889. 被引量:1
  • 6Kuti JL,Florea NR,Nightingale CH,et al.Pharmacodynamics of meropenem and imipenem against enterobacteriaceae,acinetobacter baumannii,and pseudomonas aeruginosa[J].Pharmacotherapy,2004,24(1):8-15. 被引量:1
  • 7Turner PJ.Susceptibility of meropenem and comparators tested against 30,634 enterobacteriaceae isolated in the MYSTIC programme (1997-2003)[J].Diagn Microbiol Infect Dis,2004,50(4):291 -293. 被引量:1
  • 8Yatsyk GV.Use of meropenem in the treatment of severe infections in newborns[J].Antibiot Khimioter,1998,43 (1):32-33. 被引量:1
  • 9Lumer JL,Reed MD,Kearns GL,et al.Sequential,single-dose pharmacokinefic evaluation of meropenem in hospitalized infants and children[J].Antimicrob Agents Chemother,1995,39(8):1721-1725. 被引量:1
  • 10Rhomberg PR,Jones RN,Sader HS,et al.Antimicrobial resistance rates and clonality results from the meropenem yearly susceptibility test information collection (MYSTIC) programme:Report of year five (2003)[J].Diagn Microbiol Infect Dis,2004,49(4):273-281. 被引量:1

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部